Rutger L. Van Bezooijen
Department of Endocrinology and Metabolic Diseases
Leiden University Medical Center
Leiden
Netherlands
Name/email consistency: medium
- Sclerostin in mineralized matrices and van Buchem disease. van Bezooijen, R.L., Bronckers, A.L., Gortzak, R.A., Hogendoorn, P.C., van der Wee-Pals, L., Balemans, W., Oostenbroek, H.J., Van Hul, W., Hamersma, H., Dikkers, F.G., Hamdy, N.A., Papapoulos, S.E., Löwik, C.W. J. Dent. Res. (2009)
- Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. van Bezooijen, R.L., Svensson, J.P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P.H., Vrieling, H., Papapoulos, S.E., ten Dijke, P., Löwik, C.W. J. Bone Miner. Res. (2007)
- SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. van Bezooijen, R.L., Deruiter, M.C., Vilain, N., Monteiro, R.M., Visser, A., van der Wee-Pals, L., van Munsteren, C.J., Hogendoorn, P.C., Aguet, M., Mummery, C.L., Papapoulos, S.E., Ten Dijke, P., Löwik, C.W. Dev. Dyn. (2007)
- SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. van Bezooijen, R.L., ten Dijke, P., Papapoulos, S.E., Löwik, C.W. Cytokine Growth Factor Rev. (2005)
- Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. van Bezooijen, R.L., Papapoulos, S.E., Löwik, C.W. J. Endocrinol. Invest. (2005)
- Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. van Bezooijen, R.L., Roelen, B.A., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S.E., ten Dijke, P., Löwik, C.W. J. Exp. Med. (2004)
- Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Van Bezooijen, R.L., Van Der Wee-Pals, L., Papapoulos, S.E., Löwik, C.W. Ann. Rheum. Dis. (2002)
- Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?. Van Bezooijen, R.L., Papapoulos, S.E., Löwik, C.W. Bone (2001)
